重症肌无力患者白细胞介素6水平的测定

The determination of serum interleukin-6 leveles in patients with myasthenia gravis

目的 探讨白细胞介素 6 (IL 6 )在重症肌无力 (MG)发病机制中的作用。方法 采用双抗体夹心ELISA法对 18例MG患者用糖皮质激素 (GC)治疗前、治疗 3个月后和 2 0例正常对照血清IL 6、乙酰胆碱受体抗体 (AchRab)水平进行检测。结果 MG患者组血清IL 6水平显著高于对照组 (P <0 .0 1) ,MG患者组血清IL 6水平在用GC治疗 3个月后显著降低 (P <0 .0 1) ,其血清IL 6与血清AchRab水平呈正相关 (r =0 .6 89,P <0 .0 1)。结论 IL 6与MG发病密切相关 ,IL 6参与了MG的免疫病理过程 ;检测血清IL 6水平对MG临床有重要价值 ;GC可抑制IL 6合成及Ach Rab的产生。

Objective To study the relationship between myasthenia gravis(MG) and serum interleukin-6(IL-6) levels.Methods The serum interleukin-6 and acetylcholine receptor antibody(AchRab) levels were measured in 18 MG patients before and after treatment with glucocorticosteroid(GC) and 20 normal controls(NC) with ELISA.Results The serum IL-6 levels of patients with MG were much higher than those of NC(P<0.01). The serum IL-6 and AchRab levels of MG patients dramatically decreased after 3 months treatment of GC(P<0.01).Conclusion The serum IL-6 levels are closely related to pathogenesis of MG. IL-6 might play an important role in the immunopathological process of MG. The determination of serum IL-6 levels has an important value in clinical aspects of MG. GC can suppress the synthesis of IL-6 and the production of AchRab.